Hualan Biological Engineering Inc. (SHE:002007)

Market Cap	27.48B -6.7%
Revenue (ttm)	4.60B +4.9%
Net Income	940.40M -13.6%
EPS	0.52 -13.4%
Shares Out	1.83B
PE Ratio	29.20
Forward PE	24.47
Dividend	1.00 (6.65%)
Ex-Dividend Date	Oct 27, 2025

Volume	8,348,534
Average Volume	9,754,532
Open	14.78
Previous Close	15.07
Day's Range	14.78 - 15.07
52-Week Range	14.14 - 18.39
Beta	0.45
RSI	53.14
Earnings Date	Mar 28, 2026

About SHE:002007

Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as inf...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 4,117
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002007

Financial Performance

In 2025, SHE:002007's revenue was 4.60 billion, an increase of 4.93% compared to the previous year's 4.38 billion. Earnings were 940.40 million, a decrease of -13.55%.